Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pcI-ts,ind+-(NSP8) Citations (2)

Originally described in: Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase.
Dangerfield TL, Huang NZ, Johnson KA iScience. 2020 Nov 28:101849. doi: 10.1016/j.isci.2020.101849.
PubMed Journal

Articles Citing pcI-ts,ind+-(NSP8)

Articles
Expression and purification of tag-free SARS-CoV-2 RNA-dependent RNA polymerase in Escherichia coli. Dangerfield TL, Huang NZ, Johnson KA. STAR Protoc. 2021 Mar 19;2(1):100357. doi: 10.1016/j.xpro.2021.100357. Epub 2021 Feb 4. PubMed
Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Bravo JPK, Dangerfield TL, Taylor DW, Johnson KA. Mol Cell. 2021 Apr 1;81(7):1548-1552.e4. doi: 10.1016/j.molcel.2021.01.035. Epub 2021 Jan 28. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.